Otros idiomas Adhera Therapeutics, Inc.

Acciones

ATRX

US00687E4061

Mercado cerrado - OTC Markets Otros sitios de cotización 19:00:56 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,006 ^USD	-25,93 %		+15,38 %	-80,00 %

18/01	Adhera Therapeutics, Inc. Recibe la Notificación por Escrito de Melior Pharmaceuticals II, LLC de la Elección para Terminar el Acuerdo de Licencia	CI
16/01	Adhera Therapeutics, Inc. anuncia la dimisión de Zahed Subhan como consejero delegado	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Adhera Therapeutics, Inc. Receives Written Notice from Melior Pharmaceuticals II, LLC of Election to Terminate the License Agreement	18/01
Adhera Therapeutics, Inc. Announces the Resignation of Zahed Subhan as Chief Executive Officer	16/01
Adhera Therapeutics, Inc. Announces Board Resignations	16/01
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11
BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	17/10/23
Adhera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?	10/08/23
Adhera Therapeutics, Inc. announced that it has received $0.105 million in funding	22/06/23
Adhera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	28/04/23
Adhera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
Adhera Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	31/03/23
Adhera Therapeutics, Inc. announced that it has received $0.214285 million in funding	02/03/23
Adhera Therapeutics, Inc. announced that it has received $0.364285 million in funding	16/02/23
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes	25/01/23
Adhera Therapeutics, Inc. announced that it has received $0.1 million in funding	15/12/22
Adhera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	19/09/22
Adhera Therapeutics, Inc. Elects Zahed Subhan as Chairman of the Board	19/09/22
ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)	09/09/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Adhera Therapeutics, Inc.

Acciones

ATRX

US00687E4061

Otros idiomas

Filtros